| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Streptococcus agalactiae | 44 | 2013 | 79 | 4.920 |
Why?
|
| Communicable Diseases, Emerging | 13 | 2019 | 21 | 3.420 |
Why?
|
| Disease Outbreaks | 28 | 2022 | 115 | 3.390 |
Why?
|
| Population Surveillance | 13 | 2024 | 207 | 2.690 |
Why?
|
| Streptococcal Infections | 29 | 2013 | 80 | 2.500 |
Why?
|
| Antigens, Surface | 20 | 2009 | 197 | 2.300 |
Why?
|
| Bacterial Proteins | 27 | 2013 | 768 | 2.030 |
Why?
|
| Internet | 10 | 2016 | 469 | 1.850 |
Why?
|
| Global Health | 13 | 2021 | 183 | 1.630 |
Why?
|
| Influenza, Human | 7 | 2024 | 208 | 1.340 |
Why?
|
| Epidemiological Monitoring | 8 | 2025 | 31 | 1.310 |
Why?
|
| Antigens, Bacterial | 13 | 2008 | 199 | 1.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 3 | 2014 | 90 | 1.100 |
Why?
|
| Electronic Mail | 4 | 2017 | 47 | 1.030 |
Why?
|
| Pandemics | 7 | 2024 | 673 | 0.860 |
Why?
|
| Epidemics | 4 | 2019 | 25 | 0.860 |
Why?
|
| Communicable Disease Control | 3 | 2019 | 42 | 0.840 |
Why?
|
| Public Health | 9 | 2024 | 187 | 0.800 |
Why?
|
| Vaccines | 3 | 2016 | 98 | 0.780 |
Why?
|
| Glycosaminoglycans | 3 | 2008 | 19 | 0.770 |
Why?
|
| Foodborne Diseases | 2 | 2020 | 6 | 0.710 |
Why?
|
| Vaccination | 8 | 2025 | 364 | 0.700 |
Why?
|
| Humans | 100 | 2025 | 63512 | 0.690 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 7 | 2003 | 81 | 0.680 |
Why?
|
| Massachusetts | 17 | 2025 | 2075 | 0.650 |
Why?
|
| Streptococcal Vaccines | 5 | 2008 | 5 | 0.600 |
Why?
|
| Communicable Diseases | 6 | 2017 | 90 | 0.590 |
Why?
|
| Sentinel Surveillance | 4 | 2023 | 19 | 0.570 |
Why?
|
| Antibodies, Bacterial | 13 | 2008 | 181 | 0.570 |
Why?
|
| Public Opinion | 3 | 2020 | 24 | 0.570 |
Why?
|
| Epithelial Cells | 7 | 2008 | 390 | 0.570 |
Why?
|
| Pneumococcal Infections | 4 | 2025 | 38 | 0.560 |
Why?
|
| Information Services | 2 | 2006 | 35 | 0.490 |
Why?
|
| Streptococcus pneumoniae | 5 | 2025 | 66 | 0.490 |
Why?
|
| Plant Diseases | 2 | 2014 | 12 | 0.490 |
Why?
|
| Immunization | 6 | 2016 | 133 | 0.480 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 209 | 0.470 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2014 | 1 | 0.450 |
Why?
|
| Animals | 39 | 2025 | 20666 | 0.440 |
Why?
|
| Epidemiologic Methods | 1 | 2013 | 67 | 0.400 |
Why?
|
| Respiratory Tract Infections | 2 | 2024 | 89 | 0.400 |
Why?
|
| Intensive Care Units | 2 | 2020 | 406 | 0.390 |
Why?
|
| Information Storage and Retrieval | 2 | 2009 | 60 | 0.370 |
Why?
|
| Health Status Disparities | 1 | 2013 | 146 | 0.370 |
Why?
|
| Polysaccharides, Bacterial | 6 | 2006 | 44 | 0.360 |
Why?
|
| Public Health Informatics | 1 | 2011 | 8 | 0.360 |
Why?
|
| Genome, Viral | 3 | 2021 | 136 | 0.350 |
Why?
|
| Electronic Health Records | 3 | 2024 | 361 | 0.350 |
Why?
|
| Pneumococcal Vaccines | 2 | 2025 | 21 | 0.340 |
Why?
|
| Female | 38 | 2025 | 32912 | 0.340 |
Why?
|
| Dengue | 1 | 2011 | 96 | 0.340 |
Why?
|
| Genes, Bacterial | 6 | 2006 | 120 | 0.340 |
Why?
|
| Bacterial Translocation | 2 | 2007 | 11 | 0.330 |
Why?
|
| Bacterial Vaccines | 6 | 1999 | 78 | 0.330 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2025 | 12 | 0.330 |
Why?
|
| Sequence Deletion | 3 | 2001 | 117 | 0.330 |
Why?
|
| Pregnancy | 13 | 2019 | 2335 | 0.330 |
Why?
|
| Vaccines, Conjugate | 7 | 2014 | 19 | 0.320 |
Why?
|
| Molecular Sequence Data | 15 | 2013 | 1991 | 0.320 |
Why?
|
| Mass Media | 3 | 2020 | 31 | 0.320 |
Why?
|
| Child | 9 | 2025 | 4528 | 0.320 |
Why?
|
| Pregnancy Complications, Infectious | 6 | 2014 | 65 | 0.310 |
Why?
|
| Cervix Uteri | 3 | 2007 | 60 | 0.310 |
Why?
|
| Serotyping | 11 | 2014 | 53 | 0.310 |
Why?
|
| Ebolavirus | 2 | 2022 | 39 | 0.310 |
Why?
|
| Health Services Research | 1 | 2010 | 270 | 0.310 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2013 | 480 | 0.290 |
Why?
|
| Infant, Newborn | 12 | 2022 | 1358 | 0.290 |
Why?
|
| Integrin alpha1beta1 | 1 | 2007 | 2 | 0.280 |
Why?
|
| Immunity, Maternally-Acquired | 5 | 2007 | 11 | 0.280 |
Why?
|
| Virulence Factors | 2 | 2008 | 84 | 0.270 |
Why?
|
| Child, Preschool | 8 | 2025 | 1992 | 0.270 |
Why?
|
| Zoonoses | 1 | 2006 | 9 | 0.260 |
Why?
|
| Information Dissemination | 2 | 2006 | 116 | 0.260 |
Why?
|
| Phylogeny | 5 | 2021 | 377 | 0.260 |
Why?
|
| Registries | 1 | 2010 | 893 | 0.260 |
Why?
|
| Immunoglobulin G | 5 | 2007 | 459 | 0.250 |
Why?
|
| Sepsis | 3 | 2013 | 289 | 0.250 |
Why?
|
| United States | 12 | 2024 | 7855 | 0.250 |
Why?
|
| Bacterial Capsules | 7 | 2008 | 18 | 0.230 |
Why?
|
| Public Health Surveillance | 2 | 2017 | 28 | 0.230 |
Why?
|
| Adolescent | 10 | 2025 | 6248 | 0.230 |
Why?
|
| Cattle Diseases | 1 | 2025 | 10 | 0.230 |
Why?
|
| Penicillin Resistance | 2 | 2015 | 11 | 0.230 |
Why?
|
| Mice | 21 | 2013 | 10846 | 0.230 |
Why?
|
| Milk | 1 | 2025 | 43 | 0.230 |
Why?
|
| Data Collection | 4 | 2019 | 383 | 0.230 |
Why?
|
| Bacterial Outer Membrane Proteins | 1 | 2005 | 121 | 0.220 |
Why?
|
| Tandem Repeat Sequences | 2 | 2001 | 26 | 0.220 |
Why?
|
| Anemia, Sickle Cell | 1 | 2025 | 64 | 0.220 |
Why?
|
| Drosophila melanogaster | 1 | 2008 | 489 | 0.220 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2025 | 71 | 0.220 |
Why?
|
| Biosurveillance | 2 | 2014 | 3 | 0.210 |
Why?
|
| Male | 17 | 2025 | 29927 | 0.210 |
Why?
|
| Rabbits | 11 | 2006 | 333 | 0.210 |
Why?
|
| Animals, Newborn | 9 | 2008 | 239 | 0.210 |
Why?
|
| Gene Expression Regulation, Bacterial | 3 | 2013 | 164 | 0.210 |
Why?
|
| Whole Genome Sequencing | 2 | 2021 | 82 | 0.210 |
Why?
|
| Computer Systems | 2 | 2013 | 14 | 0.200 |
Why?
|
| Algorithms | 3 | 2024 | 1003 | 0.200 |
Why?
|
| Neglected Diseases | 2 | 2014 | 11 | 0.200 |
Why?
|
| Bedding and Linens | 1 | 2023 | 5 | 0.200 |
Why?
|
| Politics | 2 | 2020 | 36 | 0.200 |
Why?
|
| Carrier Proteins | 4 | 2005 | 707 | 0.200 |
Why?
|
| Actins | 1 | 2004 | 259 | 0.190 |
Why?
|
| Hepatitis E | 1 | 2022 | 1 | 0.190 |
Why?
|
| Hepatitis E virus | 1 | 2022 | 1 | 0.190 |
Why?
|
| Penile Diseases | 1 | 2022 | 7 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2006 | 454 | 0.190 |
Why?
|
| Skin Ulcer | 1 | 2022 | 14 | 0.190 |
Why?
|
| Quarantine | 1 | 2022 | 11 | 0.190 |
Why?
|
| Rectal Diseases | 1 | 2022 | 28 | 0.190 |
Why?
|
| Exanthema | 1 | 2022 | 27 | 0.190 |
Why?
|
| Protein Binding | 5 | 2009 | 1603 | 0.190 |
Why?
|
| Viral Vaccines | 1 | 2002 | 54 | 0.190 |
Why?
|
| Base Sequence | 9 | 2009 | 1331 | 0.180 |
Why?
|
| Cholera | 2 | 2011 | 14 | 0.180 |
Why?
|
| One Health | 1 | 2021 | 2 | 0.180 |
Why?
|
| Rec A Recombinases | 1 | 2001 | 35 | 0.180 |
Why?
|
| Crowding | 1 | 2021 | 34 | 0.180 |
Why?
|
| Refugees | 1 | 2022 | 70 | 0.170 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 43 | 0.170 |
Why?
|
| Mutation | 5 | 2020 | 2615 | 0.170 |
Why?
|
| Adult | 13 | 2024 | 16837 | 0.170 |
Why?
|
| Liver Abscess | 1 | 2000 | 18 | 0.170 |
Why?
|
| Salmonella enteritidis | 1 | 2020 | 5 | 0.170 |
Why?
|
| Mosaicism | 1 | 2000 | 30 | 0.170 |
Why?
|
| Antigens, Viral | 1 | 2021 | 137 | 0.170 |
Why?
|
| Forecasting | 2 | 2019 | 232 | 0.170 |
Why?
|
| Mumps virus | 1 | 2020 | 1 | 0.160 |
Why?
|
| Cell Line | 5 | 2008 | 2040 | 0.160 |
Why?
|
| Mumps | 1 | 2020 | 2 | 0.160 |
Why?
|
| Seasons | 2 | 2024 | 134 | 0.160 |
Why?
|
| Multigene Family | 1 | 2000 | 100 | 0.160 |
Why?
|
| Infant | 6 | 2025 | 1645 | 0.160 |
Why?
|
| Schools, Medical | 1 | 2021 | 147 | 0.160 |
Why?
|
| Vagina | 2 | 2004 | 83 | 0.160 |
Why?
|
| Genome, Bacterial | 3 | 2005 | 67 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2021 | 276 | 0.160 |
Why?
|
| Emigrants and Immigrants | 1 | 2020 | 34 | 0.160 |
Why?
|
| Phagocytosis | 7 | 2008 | 264 | 0.160 |
Why?
|
| Anti-Bacterial Agents | 4 | 2014 | 790 | 0.160 |
Why?
|
| Duodenoscopes | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pain | 1 | 2022 | 406 | 0.150 |
Why?
|
| Listeriosis | 1 | 2019 | 30 | 0.150 |
Why?
|
| Risk Factors | 4 | 2023 | 5359 | 0.150 |
Why?
|
| Plants | 2 | 2012 | 49 | 0.150 |
Why?
|
| Equipment Contamination | 1 | 2019 | 33 | 0.150 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 28 | 0.150 |
Why?
|
| Monkeypox virus | 3 | 2023 | 8 | 0.150 |
Why?
|
| Amino Acid Sequence | 7 | 2007 | 1592 | 0.150 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 57 | 0.150 |
Why?
|
| Binding Sites | 4 | 2009 | 906 | 0.140 |
Why?
|
| Liver Transplantation | 1 | 2020 | 216 | 0.140 |
Why?
|
| Streptococcus | 1 | 1997 | 18 | 0.140 |
Why?
|
| Models, Statistical | 1 | 2019 | 308 | 0.140 |
Why?
|
| Young Adult | 5 | 2024 | 4700 | 0.140 |
Why?
|
| Machine Learning | 1 | 2019 | 177 | 0.140 |
Why?
|
| Epitopes | 3 | 1996 | 290 | 0.130 |
Why?
|
| Immunization, Passive | 4 | 1999 | 105 | 0.130 |
Why?
|
| Tuberculosis | 1 | 2020 | 295 | 0.130 |
Why?
|
| Incidence | 4 | 2025 | 1380 | 0.130 |
Why?
|
| Poliovirus Vaccines | 1 | 2016 | 4 | 0.120 |
Why?
|
| Cloning, Molecular | 5 | 2001 | 383 | 0.120 |
Why?
|
| Antibodies, Viral | 3 | 2022 | 327 | 0.120 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2016 | 29 | 0.120 |
Why?
|
| Protein Structure, Tertiary | 3 | 2007 | 673 | 0.120 |
Why?
|
| Mass Screening | 1 | 2021 | 691 | 0.120 |
Why?
|
| Bacterial Adhesion | 2 | 2007 | 63 | 0.120 |
Why?
|
| Uveitis | 1 | 2016 | 34 | 0.120 |
Why?
|
| Microscopy, Confocal | 2 | 2007 | 235 | 0.120 |
Why?
|
| Microbial Sensitivity Tests | 4 | 2020 | 205 | 0.110 |
Why?
|
| Bacteremia | 4 | 2015 | 94 | 0.110 |
Why?
|
| Papillomavirus Vaccines | 1 | 2016 | 69 | 0.110 |
Why?
|
| Confidentiality | 1 | 2015 | 55 | 0.110 |
Why?
|
| Leishmaniasis | 1 | 2014 | 10 | 0.110 |
Why?
|
| Virulence | 6 | 2013 | 193 | 0.110 |
Why?
|
| Critical Care | 2 | 2020 | 397 | 0.110 |
Why?
|
| Travel | 2 | 2011 | 42 | 0.110 |
Why?
|
| Comorbidity | 2 | 2014 | 1120 | 0.110 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 777 | 0.110 |
Why?
|
| Logistic Models | 2 | 2014 | 1276 | 0.110 |
Why?
|
| Databases, Factual | 2 | 2014 | 873 | 0.110 |
Why?
|
| Prospective Studies | 3 | 2018 | 3301 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 4 | 2020 | 415 | 0.100 |
Why?
|
| Boston | 2 | 2020 | 253 | 0.100 |
Why?
|
| Fimbriae, Bacterial | 1 | 2013 | 19 | 0.100 |
Why?
|
| Age Distribution | 1 | 2013 | 259 | 0.100 |
Why?
|
| Sputum | 1 | 2012 | 42 | 0.100 |
Why?
|
| Social Class | 1 | 2013 | 135 | 0.100 |
Why?
|
| Coronavirus | 1 | 2012 | 14 | 0.100 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2012 | 24 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 517 | 0.100 |
Why?
|
| Government | 1 | 2012 | 8 | 0.100 |
Why?
|
| Disease Notification | 1 | 2012 | 5 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 1147 | 0.100 |
Why?
|
| Private Sector | 1 | 2012 | 12 | 0.100 |
Why?
|
| Contact Tracing | 2 | 2022 | 17 | 0.100 |
Why?
|
| Cell Wall | 1 | 2013 | 118 | 0.100 |
Why?
|
| Middle Aged | 6 | 2024 | 17641 | 0.090 |
Why?
|
| Fungi | 1 | 2012 | 57 | 0.090 |
Why?
|
| Mycoses | 1 | 2012 | 46 | 0.090 |
Why?
|
| Ecosystem | 1 | 2012 | 53 | 0.090 |
Why?
|
| Flow Cytometry | 2 | 2004 | 664 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2007 | 1471 | 0.090 |
Why?
|
| Vibrio cholerae | 1 | 2011 | 18 | 0.090 |
Why?
|
| Molecular Epidemiology | 2 | 2021 | 32 | 0.090 |
Why?
|
| Communication | 1 | 2016 | 573 | 0.090 |
Why?
|
| Disease Models, Animal | 3 | 2013 | 2187 | 0.090 |
Why?
|
| Diarrhea | 1 | 2011 | 76 | 0.090 |
Why?
|
| Length of Stay | 1 | 2014 | 815 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2012 | 268 | 0.090 |
Why?
|
| Amino Acid Motifs | 2 | 2009 | 153 | 0.090 |
Why?
|
| Immune Sera | 4 | 1999 | 34 | 0.090 |
Why?
|
| Sex Factors | 1 | 2013 | 978 | 0.080 |
Why?
|
| Schools | 2 | 2022 | 166 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 3 | 1992 | 865 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1561 | 0.080 |
Why?
|
| Immunoglobulin M | 2 | 2007 | 115 | 0.080 |
Why?
|
| Recombinant Proteins | 4 | 2008 | 703 | 0.080 |
Why?
|
| Immunoglobulin A | 3 | 2007 | 96 | 0.080 |
Why?
|
| Asthma | 1 | 2014 | 459 | 0.080 |
Why?
|
| Central America | 1 | 2009 | 2 | 0.080 |
Why?
|
| Mexico | 1 | 2009 | 39 | 0.080 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2007 | 249 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2000 | 363 | 0.080 |
Why?
|
| Blotting, Western | 4 | 2001 | 612 | 0.070 |
Why?
|
| Species Specificity | 2 | 2006 | 334 | 0.070 |
Why?
|
| Molecular Weight | 2 | 2000 | 187 | 0.070 |
Why?
|
| Crystallography, X-Ray | 2 | 2007 | 433 | 0.070 |
Why?
|
| Lactic Acid | 1 | 2008 | 76 | 0.070 |
Why?
|
| Disease Susceptibility | 1 | 2008 | 165 | 0.070 |
Why?
|
| Streptococcus pyogenes | 2 | 2005 | 31 | 0.070 |
Why?
|
| Animals, Outbred Strains | 2 | 2007 | 7 | 0.070 |
Why?
|
| Spleen | 2 | 2001 | 484 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 194 | 0.070 |
Why?
|
| Bacterial Typing Techniques | 1 | 2007 | 12 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 2007 | 15 | 0.070 |
Why?
|
| DNA, Bacterial | 4 | 2006 | 267 | 0.060 |
Why?
|
| Time Factors | 3 | 2016 | 3770 | 0.060 |
Why?
|
| Subcellular Fractions | 2 | 2004 | 68 | 0.060 |
Why?
|
| Cross Reactions | 2 | 1997 | 133 | 0.060 |
Why?
|
| Aged | 5 | 2024 | 14469 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2006 | 79 | 0.060 |
Why?
|
| Point Mutation | 1 | 2007 | 166 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2007 | 71 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 240 | 0.060 |
Why?
|
| DNA Primers | 2 | 1996 | 293 | 0.060 |
Why?
|
| Genomics | 1 | 2009 | 371 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 191 | 0.060 |
Why?
|
| Conserved Sequence | 2 | 2009 | 173 | 0.060 |
Why?
|
| Heptavalent Pneumococcal Conjugate Vaccine | 1 | 2025 | 5 | 0.060 |
Why?
|
| Dairying | 1 | 2025 | 2 | 0.060 |
Why?
|
| Cross Infection | 1 | 2007 | 164 | 0.060 |
Why?
|
| Serogroup | 1 | 2025 | 35 | 0.060 |
Why?
|
| RNA Interference | 1 | 2008 | 618 | 0.060 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2005 | 55 | 0.060 |
Why?
|
| Retrospective Studies | 4 | 2024 | 6670 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 1553 | 0.060 |
Why?
|
| Chlorates | 1 | 2004 | 2 | 0.050 |
Why?
|
| Digitonin | 1 | 2004 | 4 | 0.050 |
Why?
|
| Cattle | 1 | 2025 | 310 | 0.050 |
Why?
|
| Cytochalasin D | 1 | 2004 | 18 | 0.050 |
Why?
|
| Polysaccharide-Lyases | 1 | 2004 | 3 | 0.050 |
Why?
|
| Cytotoxins | 1 | 2004 | 12 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2005 | 299 | 0.050 |
Why?
|
| World Health Organization | 2 | 2016 | 34 | 0.050 |
Why?
|
| Immunoassay | 1 | 2004 | 70 | 0.050 |
Why?
|
| Codon, Initiator | 1 | 2003 | 11 | 0.050 |
Why?
|
| Hospitals | 1 | 2007 | 394 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2007 | 1150 | 0.050 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 49 | 0.050 |
Why?
|
| Bacterial Toxins | 1 | 2004 | 61 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 150 | 0.050 |
Why?
|
| Luminescent Proteins | 1 | 2003 | 128 | 0.050 |
Why?
|
| Lung | 1 | 2008 | 956 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2024 | 120 | 0.050 |
Why?
|
| Cytosol | 1 | 2004 | 180 | 0.050 |
Why?
|
| Heparin | 1 | 2004 | 116 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2013 | 3035 | 0.050 |
Why?
|
| Trifluridine | 1 | 2022 | 1 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2005 | 410 | 0.050 |
Why?
|
| Isoindoles | 1 | 2022 | 3 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2003 | 257 | 0.050 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2002 | 5 | 0.050 |
Why?
|
| Cytoplasm | 1 | 2004 | 276 | 0.050 |
Why?
|
| Syndrome | 1 | 2023 | 181 | 0.050 |
Why?
|
| Immunization Schedule | 1 | 2002 | 18 | 0.050 |
Why?
|
| Protein Transport | 1 | 2004 | 402 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 53 | 0.050 |
Why?
|
| Anus Diseases | 1 | 2022 | 8 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 14 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 21 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2003 | 542 | 0.050 |
Why?
|
| Cell Polarity | 1 | 2002 | 109 | 0.050 |
Why?
|
| Kinetics | 1 | 2004 | 763 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2003 | 367 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 122 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 864 | 0.050 |
Why?
|
| Microfluidics | 1 | 2022 | 25 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 114 | 0.050 |
Why?
|
| Biological Transport | 1 | 2002 | 291 | 0.050 |
Why?
|
| Neonatal Screening | 1 | 2022 | 98 | 0.050 |
Why?
|
| Genetic Variation | 3 | 2007 | 383 | 0.050 |
Why?
|
| Masks | 1 | 2021 | 23 | 0.050 |
Why?
|
| Dominican Republic | 2 | 2011 | 25 | 0.050 |
Why?
|
| Rectum | 1 | 2022 | 91 | 0.050 |
Why?
|
| Models, Animal | 1 | 2002 | 237 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2004 | 496 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2021 | 33 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2005 | 76 | 0.040 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 200 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2009 | 1513 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 62 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2021 | 29 | 0.040 |
Why?
|
| Rectal Neoplasms | 1 | 2022 | 111 | 0.040 |
Why?
|
| Suppuration | 1 | 2000 | 11 | 0.040 |
Why?
|
| Repetitive Sequences, Amino Acid | 1 | 2000 | 8 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 1186 | 0.040 |
Why?
|
| Open Reading Frames | 1 | 2000 | 84 | 0.040 |
Why?
|
| Authoritarianism | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cytokines | 1 | 2004 | 935 | 0.040 |
Why?
|
| Candida | 1 | 2020 | 40 | 0.040 |
Why?
|
| Prejudice | 1 | 2020 | 62 | 0.040 |
Why?
|
| Tetanus Toxoid | 1 | 1999 | 14 | 0.040 |
Why?
|
| Temperature | 1 | 2021 | 307 | 0.040 |
Why?
|
| Community Health Services | 1 | 2021 | 128 | 0.040 |
Why?
|
| Drainage | 1 | 2000 | 154 | 0.040 |
Why?
|
| Antifungal Agents | 1 | 2020 | 129 | 0.040 |
Why?
|
| Colistin | 1 | 2019 | 7 | 0.040 |
Why?
|
| Enterococcus faecium | 1 | 1999 | 7 | 0.040 |
Why?
|
| Listeria monocytogenes | 1 | 2019 | 34 | 0.040 |
Why?
|
| Enterococcus faecalis | 1 | 1999 | 12 | 0.040 |
Why?
|
| Gene Expression | 2 | 2005 | 840 | 0.040 |
Why?
|
| Students | 1 | 2021 | 218 | 0.040 |
Why?
|
| Food Handling | 1 | 2019 | 53 | 0.040 |
Why?
|
| Vancomycin | 1 | 1999 | 39 | 0.040 |
Why?
|
| Lethal Dose 50 | 1 | 1998 | 16 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2000 | 485 | 0.040 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 251 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 1997 | 12 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2020 | 263 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 182 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 663 | 0.030 |
Why?
|
| Academies and Institutes | 1 | 2017 | 25 | 0.030 |
Why?
|
| Software Design | 1 | 2017 | 28 | 0.030 |
Why?
|
| Information Systems | 1 | 2017 | 29 | 0.030 |
Why?
|
| Climate Change | 1 | 2017 | 23 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 5471 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 434 | 0.030 |
Why?
|
| Fetal Blood | 2 | 2007 | 73 | 0.030 |
Why?
|
| Antibody Specificity | 2 | 2007 | 102 | 0.030 |
Why?
|
| Immunochemistry | 1 | 1997 | 10 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2017 | 105 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 600 | 0.030 |
Why?
|
| Trypsin | 1 | 1996 | 39 | 0.030 |
Why?
|
| Antibody Affinity | 1 | 1996 | 19 | 0.030 |
Why?
|
| Vaccines, Synthetic | 1 | 1997 | 78 | 0.030 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1008 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2017 | 173 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 154 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2017 | 231 | 0.030 |
Why?
|
| Liberia | 1 | 2016 | 11 | 0.030 |
Why?
|
| Pakistan | 1 | 2016 | 17 | 0.030 |
Why?
|
| Health Personnel | 1 | 2020 | 367 | 0.030 |
Why?
|
| Endopeptidases | 2 | 1999 | 67 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 1996 | 373 | 0.030 |
Why?
|
| Meningitis, Pneumococcal | 1 | 2015 | 1 | 0.030 |
Why?
|
| Epidemiology | 1 | 2015 | 6 | 0.030 |
Why?
|
| Penicillins | 1 | 2014 | 30 | 0.030 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2014 | 16 | 0.030 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2014 | 14 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 313 | 0.030 |
Why?
|
| Escherichia coli | 2 | 1997 | 707 | 0.030 |
Why?
|
| France | 1 | 2014 | 14 | 0.030 |
Why?
|
| Poisson Distribution | 1 | 2014 | 53 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2007 | 1119 | 0.030 |
Why?
|
| Social Media | 1 | 2016 | 128 | 0.030 |
Why?
|
| Tomography, Optical Coherence | 1 | 2016 | 224 | 0.030 |
Why?
|
| Heat-Shock Response | 1 | 2013 | 34 | 0.030 |
Why?
|
| Middle East | 1 | 2012 | 11 | 0.020 |
Why?
|
| Opsonin Proteins | 2 | 2005 | 30 | 0.020 |
Why?
|
| Extinction, Biological | 1 | 2012 | 8 | 0.020 |
Why?
|
| Pneumonia, Bacterial | 1 | 2013 | 89 | 0.020 |
Why?
|
| Vibrio cholerae O1 | 1 | 2011 | 3 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2015 | 268 | 0.020 |
Why?
|
| Haiti | 1 | 2011 | 15 | 0.020 |
Why?
|
| Food Supply | 1 | 2012 | 53 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 1 | 1991 | 26 | 0.020 |
Why?
|
| Educational Status | 1 | 2012 | 275 | 0.020 |
Why?
|
| Fluid Therapy | 1 | 2011 | 47 | 0.020 |
Why?
|
| Immunoblotting | 1 | 1991 | 204 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 1997 | 895 | 0.020 |
Why?
|
| Feces | 1 | 2011 | 112 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 90 | 0.020 |
Why?
|
| Poverty | 1 | 2012 | 296 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1094 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 672 | 0.020 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 1989 | 8 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 1991 | 883 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2008 | 51 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2008 | 69 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 980 | 0.020 |
Why?
|
| Fetus | 1 | 2008 | 99 | 0.020 |
Why?
|
| Phenotype | 1 | 1991 | 1207 | 0.020 |
Why?
|
| HL-60 Cells | 1 | 2007 | 25 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2008 | 458 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 1364 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 1989 | 567 | 0.020 |
Why?
|
| Immunodiffusion | 1 | 2006 | 5 | 0.020 |
Why?
|
| Multiple Myeloma | 1 | 1991 | 348 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 676 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2007 | 309 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2005 | 41 | 0.010 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 2005 | 10 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 2681 | 0.010 |
Why?
|
| Crystallization | 1 | 2005 | 99 | 0.010 |
Why?
|
| Rats | 1 | 2008 | 1980 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2004 | 88 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2004 | 160 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2014 | 5699 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 356 | 0.010 |
Why?
|
| Neutrophils | 1 | 2005 | 377 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 615 | 0.010 |
Why?
|
| Biological Evolution | 1 | 2002 | 122 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2002 | 297 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 2157 | 0.010 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1999 | 3 | 0.010 |
Why?
|
| Peritoneum | 1 | 1999 | 30 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1999 | 46 | 0.010 |
Why?
|
| Uterus | 1 | 1999 | 42 | 0.010 |
Why?
|
| Biomass | 1 | 1999 | 28 | 0.010 |
Why?
|
| Cell Fractionation | 1 | 1999 | 32 | 0.010 |
Why?
|
| Random Allocation | 1 | 1999 | 199 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1999 | 98 | 0.010 |
Why?
|
| Hemolysin Proteins | 1 | 1999 | 44 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1999 | 47 | 0.010 |
Why?
|
| Gestational Age | 1 | 1999 | 189 | 0.010 |
Why?
|
| Epitope Mapping | 1 | 1997 | 50 | 0.010 |
Why?
|
| Immunodominant Epitopes | 1 | 1997 | 57 | 0.010 |
Why?
|
| Spain | 1 | 1993 | 33 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1993 | 59 | 0.010 |
Why?
|
| TATA Box | 1 | 1992 | 11 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 52 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1992 | 55 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 182 | 0.010 |
Why?
|
| Plasmids | 1 | 1991 | 292 | 0.010 |
Why?
|
| DNA Transposable Elements | 1 | 1991 | 140 | 0.010 |
Why?
|
| Mycobacterium avium Complex | 1 | 1989 | 3 | 0.000 |
Why?
|
| Prevalence | 1 | 1993 | 1380 | 0.000 |
Why?
|
| Toxoplasma | 1 | 1989 | 33 | 0.000 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1989 | 137 | 0.000 |
Why?
|
| Monocytes | 1 | 1989 | 353 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1989 | 256 | 0.000 |
Why?
|
| Macrophages | 1 | 1989 | 1039 | 0.000 |
Why?
|